^
Association details:
| Biomarker: | B4GALNT1 expression |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | Qarziba (dinutuximab beta) (GD2 ganglioside inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Published date:
05/27/2022
Excerpt:
Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option...
DOI:
10.1097/MPH.0000000000002488
